These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 30725204)
21. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression. Shimada K; Tomita A; Saito S; Kiyoi H Br J Haematol; 2014 Aug; 166(3):455-7. PubMed ID: 24673649 [No Abstract] [Full Text] [Related]
23. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228 [TBL] [Abstract][Full Text] [Related]
24. Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies. Prantl L; Heider P; Bergmeister L; Calana K; Bohn JP; Wolf D; Banki Z; Bosch A; Plach M; Huber G; Schrödel S; Thirion C; Stoiber H Front Immunol; 2024; 15():1379023. PubMed ID: 39104533 [TBL] [Abstract][Full Text] [Related]
25. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Czuczman MS; Gregory SA Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564 [TBL] [Abstract][Full Text] [Related]
26. Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells. Cavallini C; Galasso M; Pozza ED; Chignola R; Lovato O; Dando I; Romanelli MG; Krampera M; Pizzolo G; Donadelli M; Scupoli MT Br J Haematol; 2021 Jan; 192(2):333-342. PubMed ID: 33216963 [TBL] [Abstract][Full Text] [Related]
27. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies. Qi J; Chen SS; Chiorazzi N; Rader C Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356 [TBL] [Abstract][Full Text] [Related]
28. Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion. Borsky M; Hrabcakova V; Novotna J; Brychtova Y; Doubek M; Panovska A; Muller P; Mayer J; Trbusek M; Mraz M Leuk Res; 2021 Dec; 111():106684. PubMed ID: 34438120 [TBL] [Abstract][Full Text] [Related]
29. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640 [TBL] [Abstract][Full Text] [Related]
30. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. Church AK; VanDerMeid KR; Baig NA; Baran AM; Witzig TE; Nowakowski GS; Zent CS Clin Exp Immunol; 2016 Jan; 183(1):90-101. PubMed ID: 26307241 [TBL] [Abstract][Full Text] [Related]
31. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239 [TBL] [Abstract][Full Text] [Related]
32. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315 [TBL] [Abstract][Full Text] [Related]
33. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Teeling JL; French RR; Cragg MS; van den Brakel J; Pluyter M; Huang H; Chan C; Parren PW; Hack CE; Dechant M; Valerius T; van de Winkel JG; Glennie MJ Blood; 2004 Sep; 104(6):1793-800. PubMed ID: 15172969 [TBL] [Abstract][Full Text] [Related]